How much does ezetimibe lower LDL?

Ezetimibe monotherapy reduces LDL by approximately 15-22%. When added to a statin, it provides an additional 18-25% reduction on top of the statin's effect — a synergistic benefit because blocking both synthesis (statin) and absorption (ezetimibe) is more effective than either alone.

Does ezetimibe reduce cardiovascular events?

Yes — the IMPROVE-IT trial demonstrated that adding ezetimibe to simvastatin reduced the composite CV endpoint (CV death, MI, stroke, hospitalization) by 6.4% relative to simvastatin alone in post-ACS patients, establishing that further LDL reduction beyond statins translates to CV benefit.

Is ezetimibe safe to combine with rosuvastatin?

Yes — ezetimibe is routinely combined with all statins, including rosuvastatin. The combination (rosuvastatin + ezetimibe) is available as a branded product (Roszet) and provides additive LDL lowering with no significant increase in side effects versus rosuvastatin alone.

NPC1L1 Inhibitor • Oral • Rx

Ezetimibe: The Complementary Stacker That Blocks Cholesterol Absorption

Q: What is ezetimibe?

Ezetimibe (Zetia) is a cholesterol absorption inhibitor that works by blocking the NPC1L1 transporter in intestinal cells, preventing dietary and biliary cholesterol from entering the bloodstream. Unlike statins, it does not inhibit hepatic synthesis — the two mechanisms are complementary.

By MeetPeptide Research Team

Last updated: March 2026

Ezetimibe blocks the NPC1L1 transporter in intestinal brush border cells, preventing dietary and biliary cholesterol from entering circulation. Stacked with a statin, it provides additive LDL reduction through an entirely separate mechanism — proven to reduce cardiovascular events in the landmark IMPROVE-IT trial.

Fixed Daily Dose
Single Oral Tablet

Additional LDL Reduction
Added to Statin

CV Event Reduction
IMPROVE-IT Trial

Mechanism of Action

How Ezetimibe Works

Ezetimibe selectively inhibits the Niemann-Pick C1-Like 1 (NPC1L1) protein — the primary transporter responsible for intestinal cholesterol absorption. It is localized to the brush border of small intestinal enterocytes and blocks both dietary cholesterol (~300mg/day) and the much larger biliary cholesterol pool (~800-1200mg/day) from being absorbed. This is complementary to — not duplicative of — statin therapy.

🚧

NPC1L1 Transporter Blockade

Ezetimibe and its active glucuronide metabolite bind to and inhibit the NPC1L1 protein in the brush border of duodenal and jejunal enterocytes. NPC1L1 is the primary route for cholesterol uptake from the intestinal lumen into enterocytes. By blocking it, ezetimibe reduces cholesterol delivery to the liver by ~50%, regardless of whether cholesterol is dietary or from bile.

🔁

Complementary to Statins — Not Redundant

Statins block hepatic cholesterol synthesis, triggering compensatory increases in intestinal cholesterol absorption and LDL receptor upregulation. Ezetimibe blocks this absorption compensation — so when combined with a statin, both synthesis AND absorption are inhibited. This synergy explains why the combination achieves 50-65% LDL reduction vs 35-55% with statin alone.

🧬

Hepatic LDL Receptor Upregulation

Reduced cholesterol delivery to the liver from the intestine activates SREBP-2 transcription, upregulating hepatic LDL receptors. More LDL receptors clear more LDL particles from plasma. This is the same pathway statins exploit — ezetimibe activates it via intestinal cholesterol depletion rather than synthesis inhibition, making them additive.

💊

Pharmacokinetics — Enterohepatic Circulation

Ezetimibe is absorbed and rapidly glucuronidated in the intestinal wall and liver. The active glucuronide undergoes extensive enterohepatic recirculation — it is excreted in bile, re-enters the intestine, and inhibits NPC1L1 repeatedly throughout the day. This explains why a single 10mg dose provides sustained 24-hour inhibition and why no dose titration exists.

Research Data

What the Clinical Trials Show

Data from IMPROVE-IT, SHARP, and pooled ezetimibe clinical program trials.

LDL Reduction — Monotherapy (10mg)

Ezetimibe alone vs placebo in pooled clinical trials

~18%

Additional LDL Reduction Added to Statin

Incremental LDL lowering on top of statin baseline

+18-25%

CV Event Reduction (IMPROVE-IT)

Composite CV endpoint vs simvastatin alone — post-ACS patients

−6.4%

Cholesterol Absorption Inhibition

Reduction in intestinal cholesterol absorption (dietary + biliary)

~54%

SHARP Trial — CKD Patients

Simvastatin/ezetimibe vs placebo: major atherosclerotic event reduction

−17%

Safety Profile

Side Effects & Risks

Diarrhea / GI Upset

Altered intestinal cholesterol transport — usually mild and transient

~4%

Myalgia (Muscle Aches)

Rare as monotherapy; combined statin risk similar to statin alone

~3%

Elevated Liver Enzymes

Transaminase elevation >3x ULN — similar to placebo as monotherapy

<1%

Headache

Most common adverse event in clinical trials

~6%

Cholelithiasis (Gallstones)

Theoretical risk from altered biliary cholesterol flux — not confirmed in trials

Theoretical

Bottom Line

Key Takeaways

✅ What We Know

Blocks NPC1L1 — reduces intestinal cholesterol absorption ~54%
Adds 18-25% LDL reduction ON TOP of statin therapy
Reduces CV events 6.4% vs statin alone (IMPROVE-IT, post-ACS)
Excellent safety profile — side effects comparable to placebo in trials
One dose fits all — 10mg flat, no titration required
Synergistic with statins via complementary, non-overlapping mechanisms

⚠️ What We Don't Know

Outcome data in bodybuilders and AAS/TRT users specifically
Whether monotherapy (without statin) provides meaningful CV benefit
Long-term impact on fat-soluble vitamin absorption at very high doses
Effect on cholesterol absorption in high-fat/high-cholesterol athlete diets

📚

Want the Complete Protocol Guide?

Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.

Get the Guide →

⚠️ Important Disclaimer

This page is for educational purposes only. It is not medical advice. Ezetimibe is a prescription medication. All lipid management should be supervised by a physician with periodic lipid panel monitoring. Do not adjust statin or ezetimibe doses without medical guidance.